ZA200103314B - A pharmaceutical composition for treating immune diseases. - Google Patents
A pharmaceutical composition for treating immune diseases. Download PDFInfo
- Publication number
- ZA200103314B ZA200103314B ZA200103314A ZA200103314A ZA200103314B ZA 200103314 B ZA200103314 B ZA 200103314B ZA 200103314 A ZA200103314 A ZA 200103314A ZA 200103314 A ZA200103314 A ZA 200103314A ZA 200103314 B ZA200103314 B ZA 200103314B
- Authority
- ZA
- South Africa
- Prior art keywords
- ailim
- cells
- antibody
- pharmaceutical composition
- substance
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 81
- 208000026278 immune system disease Diseases 0.000 title description 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 343
- 210000004027 cell Anatomy 0.000 claims description 263
- 239000000126 substance Substances 0.000 claims description 100
- 238000004519 manufacturing process Methods 0.000 claims description 88
- 108090000623 proteins and genes Proteins 0.000 claims description 88
- 239000000427 antigen Substances 0.000 claims description 83
- 108091007433 antigens Proteins 0.000 claims description 83
- 102000036639 antigens Human genes 0.000 claims description 83
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 68
- 102000004127 Cytokines Human genes 0.000 claims description 66
- 108090000695 Cytokines Proteins 0.000 claims description 66
- 229920001184 polypeptide Polymers 0.000 claims description 65
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 65
- 230000002401 inhibitory effect Effects 0.000 claims description 54
- 208000024908 graft versus host disease Diseases 0.000 claims description 52
- 230000035755 proliferation Effects 0.000 claims description 48
- 102000004169 proteins and genes Human genes 0.000 claims description 45
- 230000000694 effects Effects 0.000 claims description 37
- 230000004663 cell proliferation Effects 0.000 claims description 36
- 206010061218 Inflammation Diseases 0.000 claims description 35
- 230000004054 inflammatory process Effects 0.000 claims description 35
- 230000001404 mediated effect Effects 0.000 claims description 35
- 201000008482 osteoarthritis Diseases 0.000 claims description 32
- 102000004388 Interleukin-4 Human genes 0.000 claims description 30
- 108090000978 Interleukin-4 Proteins 0.000 claims description 30
- 229940028885 interleukin-4 Drugs 0.000 claims description 30
- 230000019491 signal transduction Effects 0.000 claims description 29
- 230000004927 fusion Effects 0.000 claims description 22
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 22
- 208000006454 hepatitis Diseases 0.000 claims description 21
- 231100000283 hepatitis Toxicity 0.000 claims description 21
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 claims description 15
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 claims description 15
- 238000011321 prophylaxis Methods 0.000 claims description 14
- 150000001875 compounds Chemical class 0.000 claims description 13
- 102000014150 Interferons Human genes 0.000 claims description 12
- 108010050904 Interferons Proteins 0.000 claims description 12
- 239000003937 drug carrier Substances 0.000 claims description 12
- 229940079322 interferon Drugs 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 11
- 230000028993 immune response Effects 0.000 claims description 10
- 210000000056 organ Anatomy 0.000 claims description 7
- 238000002054 transplantation Methods 0.000 claims description 6
- 101001042104 Homo sapiens Inducible T-cell costimulator Proteins 0.000 claims 24
- 102100021317 Inducible T-cell costimulator Human genes 0.000 claims 24
- 230000014509 gene expression Effects 0.000 description 150
- 241000699666 Mus <mouse, genus> Species 0.000 description 121
- 241000282414 Homo sapiens Species 0.000 description 115
- 210000005259 peripheral blood Anatomy 0.000 description 72
- 239000011886 peripheral blood Substances 0.000 description 72
- 238000000034 method Methods 0.000 description 66
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 63
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 63
- 238000012360 testing method Methods 0.000 description 62
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 description 59
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 59
- 230000000638 stimulation Effects 0.000 description 51
- 108020004414 DNA Proteins 0.000 description 45
- 241000700159 Rattus Species 0.000 description 43
- 210000004698 lymphocyte Anatomy 0.000 description 39
- 238000007799 mixed lymphocyte reaction assay Methods 0.000 description 33
- 210000001541 thymus gland Anatomy 0.000 description 33
- 108060003951 Immunoglobulin Proteins 0.000 description 32
- 102000018358 immunoglobulin Human genes 0.000 description 32
- 230000001965 increasing effect Effects 0.000 description 32
- 210000004408 hybridoma Anatomy 0.000 description 30
- 230000006698 induction Effects 0.000 description 30
- 235000018102 proteins Nutrition 0.000 description 30
- 210000000952 spleen Anatomy 0.000 description 30
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 29
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 29
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 27
- 230000000139 costimulatory effect Effects 0.000 description 26
- 210000004989 spleen cell Anatomy 0.000 description 26
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 25
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 23
- 239000002773 nucleotide Substances 0.000 description 23
- 125000003729 nucleotide group Chemical group 0.000 description 23
- 208000009329 Graft vs Host Disease Diseases 0.000 description 22
- 230000004913 activation Effects 0.000 description 22
- 241000699670 Mus sp. Species 0.000 description 20
- 210000001165 lymph node Anatomy 0.000 description 20
- 238000004458 analytical method Methods 0.000 description 19
- 230000004936 stimulating effect Effects 0.000 description 19
- 210000001519 tissue Anatomy 0.000 description 19
- 108010062580 Concanavalin A Proteins 0.000 description 18
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 18
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 17
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 17
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 description 17
- 241001465754 Metazoa Species 0.000 description 17
- 239000002671 adjuvant Substances 0.000 description 17
- 238000006243 chemical reaction Methods 0.000 description 17
- 201000010099 disease Diseases 0.000 description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 17
- PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 17
- 230000006052 T cell proliferation Effects 0.000 description 16
- 125000003275 alpha amino acid group Chemical group 0.000 description 16
- 206010003246 arthritis Diseases 0.000 description 16
- 239000000243 solution Substances 0.000 description 16
- 102100034980 ICOS ligand Human genes 0.000 description 15
- 239000012228 culture supernatant Substances 0.000 description 15
- 239000012634 fragment Substances 0.000 description 15
- 239000013642 negative control Substances 0.000 description 15
- 108010031485 4-hydroxy-3-nitrophenylacetyl-keyhole limpet hemocyanin Proteins 0.000 description 14
- 210000000612 antigen-presenting cell Anatomy 0.000 description 14
- 230000006870 function Effects 0.000 description 14
- 230000005764 inhibitory process Effects 0.000 description 14
- 108010002350 Interleukin-2 Proteins 0.000 description 13
- 102000000588 Interleukin-2 Human genes 0.000 description 13
- 235000001014 amino acid Nutrition 0.000 description 13
- 150000001413 amino acids Chemical class 0.000 description 13
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 13
- 230000003053 immunization Effects 0.000 description 13
- 239000011325 microbead Substances 0.000 description 13
- 230000036961 partial effect Effects 0.000 description 13
- 239000012980 RPMI-1640 medium Substances 0.000 description 12
- 210000003719 b-lymphocyte Anatomy 0.000 description 12
- 208000023275 Autoimmune disease Diseases 0.000 description 11
- 241000699800 Cricetinae Species 0.000 description 11
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 11
- 230000006044 T cell activation Effects 0.000 description 11
- 230000005867 T cell response Effects 0.000 description 11
- 239000012894 fetal calf serum Substances 0.000 description 11
- 239000007924 injection Substances 0.000 description 11
- 238000002347 injection Methods 0.000 description 11
- 239000002555 ionophore Substances 0.000 description 11
- 230000000236 ionophoric effect Effects 0.000 description 11
- 210000003563 lymphoid tissue Anatomy 0.000 description 11
- 229940104230 thymidine Drugs 0.000 description 11
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 10
- 241000186427 Cutibacterium acnes Species 0.000 description 10
- 238000002965 ELISA Methods 0.000 description 10
- 101100179074 Homo sapiens ICOS gene Proteins 0.000 description 10
- 101001019455 Homo sapiens ICOS ligand Proteins 0.000 description 10
- 108091008874 T cell receptors Proteins 0.000 description 10
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 10
- 238000002649 immunization Methods 0.000 description 10
- 238000010348 incorporation Methods 0.000 description 10
- 230000001939 inductive effect Effects 0.000 description 10
- 239000002609 medium Substances 0.000 description 10
- 238000011282 treatment Methods 0.000 description 10
- 206010035226 Plasma cell myeloma Diseases 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 238000012258 culturing Methods 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- 238000001727 in vivo Methods 0.000 description 9
- 239000003446 ligand Substances 0.000 description 9
- 201000000050 myeloid neoplasm Diseases 0.000 description 9
- 238000011740 C57BL/6 mouse Methods 0.000 description 8
- 241000124008 Mammalia Species 0.000 description 8
- 241000283973 Oryctolagus cuniculus Species 0.000 description 8
- 206010070834 Sensitisation Diseases 0.000 description 8
- 239000011324 bead Substances 0.000 description 8
- 210000000170 cell membrane Anatomy 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 239000013604 expression vector Substances 0.000 description 8
- 230000003993 interaction Effects 0.000 description 8
- 230000037361 pathway Effects 0.000 description 8
- 239000008363 phosphate buffer Substances 0.000 description 8
- 239000013641 positive control Substances 0.000 description 8
- 230000008313 sensitization Effects 0.000 description 8
- 239000000725 suspension Substances 0.000 description 8
- 230000008961 swelling Effects 0.000 description 8
- 230000001225 therapeutic effect Effects 0.000 description 8
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 7
- 201000004624 Dermatitis Diseases 0.000 description 7
- 201000003066 Diffuse Scleroderma Diseases 0.000 description 7
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 7
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 7
- 102000003814 Interleukin-10 Human genes 0.000 description 7
- 108090000174 Interleukin-10 Proteins 0.000 description 7
- 201000009594 Systemic Scleroderma Diseases 0.000 description 7
- 206010042953 Systemic sclerosis Diseases 0.000 description 7
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 7
- 101150014721 cdr gene Proteins 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- 230000016396 cytokine production Effects 0.000 description 7
- 230000007246 mechanism Effects 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 210000001179 synovial fluid Anatomy 0.000 description 7
- 229910052722 tritium Inorganic materials 0.000 description 7
- 239000013598 vector Substances 0.000 description 7
- 241000700199 Cavia porcellus Species 0.000 description 6
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 6
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 6
- 101100179075 Mus musculus Icos gene Proteins 0.000 description 6
- 229940098773 bovine serum albumin Drugs 0.000 description 6
- 239000011575 calcium Substances 0.000 description 6
- 230000021164 cell adhesion Effects 0.000 description 6
- 239000006285 cell suspension Substances 0.000 description 6
- 230000000875 corresponding effect Effects 0.000 description 6
- 230000017307 interleukin-4 production Effects 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 230000035772 mutation Effects 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 239000013589 supplement Substances 0.000 description 6
- 238000010361 transduction Methods 0.000 description 6
- 230000026683 transduction Effects 0.000 description 6
- 238000011725 BALB/c mouse Methods 0.000 description 5
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 5
- 206010011968 Decreased immune responsiveness Diseases 0.000 description 5
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 5
- 101710093458 ICOS ligand Proteins 0.000 description 5
- 101001042093 Mus musculus ICOS ligand Proteins 0.000 description 5
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 5
- 108091034117 Oligonucleotide Proteins 0.000 description 5
- 102100040247 Tumor necrosis factor Human genes 0.000 description 5
- 210000000628 antibody-producing cell Anatomy 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 108020001507 fusion proteins Proteins 0.000 description 5
- 102000037865 fusion proteins Human genes 0.000 description 5
- 210000005087 mononuclear cell Anatomy 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 230000008054 signal transmission Effects 0.000 description 5
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 5
- 230000001960 triggered effect Effects 0.000 description 5
- 206010003445 Ascites Diseases 0.000 description 4
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 4
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 4
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 4
- 108700031361 Brachyury Proteins 0.000 description 4
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 description 4
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 4
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 4
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 4
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 4
- 239000004365 Protease Substances 0.000 description 4
- 241000700157 Rattus norvegicus Species 0.000 description 4
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 4
- 230000003213 activating effect Effects 0.000 description 4
- 230000008827 biological function Effects 0.000 description 4
- 230000033228 biological regulation Effects 0.000 description 4
- 238000007385 chemical modification Methods 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 4
- 230000001086 cytosolic effect Effects 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 238000010353 genetic engineering Methods 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 102000043321 human CTLA4 Human genes 0.000 description 4
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 210000004379 membrane Anatomy 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 239000003226 mitogen Substances 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 201000008383 nephritis Diseases 0.000 description 4
- 229940055019 propionibacterium acne Drugs 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 4
- 230000009261 transgenic effect Effects 0.000 description 4
- 108091005703 transmembrane proteins Proteins 0.000 description 4
- 102000035160 transmembrane proteins Human genes 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- KEWSCDNULKOKTG-UHFFFAOYSA-N 4-cyano-4-ethylsulfanylcarbothioylsulfanylpentanoic acid Chemical compound CCSC(=S)SC(C)(C#N)CCC(O)=O KEWSCDNULKOKTG-UHFFFAOYSA-N 0.000 description 3
- KKJUPNGICOCCDW-UHFFFAOYSA-N 7-N,N-Dimethylamino-1,2,3,4,5-pentathiocyclooctane Chemical compound CN(C)C1CSSSSSC1 KKJUPNGICOCCDW-UHFFFAOYSA-N 0.000 description 3
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 3
- 108020004491 Antisense DNA Proteins 0.000 description 3
- 206010003210 Arteriosclerosis Diseases 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 3
- 102000002110 C2 domains Human genes 0.000 description 3
- 108050009459 C2 domains Proteins 0.000 description 3
- 101100326581 Caenorhabditis elegans cdh-4 gene Proteins 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 241000283707 Capra Species 0.000 description 3
- 102100037637 Cholesteryl ester transfer protein Human genes 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 208000004232 Enteritis Diseases 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 208000007882 Gastritis Diseases 0.000 description 3
- 206010018364 Glomerulonephritis Diseases 0.000 description 3
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 3
- 101100166600 Homo sapiens CD28 gene Proteins 0.000 description 3
- 101000880514 Homo sapiens Cholesteryl ester transfer protein Proteins 0.000 description 3
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 3
- 208000034486 Multi-organ failure Diseases 0.000 description 3
- 208000010718 Multiple Organ Failure Diseases 0.000 description 3
- 208000007201 Myocardial reperfusion injury Diseases 0.000 description 3
- 208000009525 Myocarditis Diseases 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- 108090000526 Papain Proteins 0.000 description 3
- 241001494479 Pecora Species 0.000 description 3
- 108010004729 Phycoerythrin Proteins 0.000 description 3
- 206010035664 Pneumonia Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 201000004681 Psoriasis Diseases 0.000 description 3
- 108020004511 Recombinant DNA Proteins 0.000 description 3
- 206010063837 Reperfusion injury Diseases 0.000 description 3
- 206010039710 Scleroderma Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 230000033289 adaptive immune response Effects 0.000 description 3
- 208000026935 allergic disease Diseases 0.000 description 3
- 230000000172 allergic effect Effects 0.000 description 3
- 239000003816 antisense DNA Substances 0.000 description 3
- 208000011775 arteriosclerosis disease Diseases 0.000 description 3
- 208000010668 atopic eczema Diseases 0.000 description 3
- 230000005540 biological transmission Effects 0.000 description 3
- 206010006451 bronchitis Diseases 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 230000024245 cell differentiation Effects 0.000 description 3
- 230000032823 cell division Effects 0.000 description 3
- 201000008191 cerebritis Diseases 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 238000012137 double-staining Methods 0.000 description 3
- 206010014599 encephalitis Diseases 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 210000002443 helper t lymphocyte Anatomy 0.000 description 3
- 238000009396 hybridization Methods 0.000 description 3
- 230000002519 immonomodulatory effect Effects 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 230000002163 immunogen Effects 0.000 description 3
- 208000027866 inflammatory disease Diseases 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 239000007928 intraperitoneal injection Substances 0.000 description 3
- 201000011486 lichen planus Diseases 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 210000001616 monocyte Anatomy 0.000 description 3
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 description 3
- 210000000822 natural killer cell Anatomy 0.000 description 3
- 229940055729 papain Drugs 0.000 description 3
- 235000019834 papain Nutrition 0.000 description 3
- 206010034674 peritonitis Diseases 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 108091008146 restriction endonucleases Proteins 0.000 description 3
- 238000002741 site-directed mutagenesis Methods 0.000 description 3
- 230000002269 spontaneous effect Effects 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- IQUPABOKLQSFBK-UHFFFAOYSA-N 2-nitrophenol Chemical compound OC1=CC=CC=C1[N+]([O-])=O IQUPABOKLQSFBK-UHFFFAOYSA-N 0.000 description 2
- 229930024421 Adenine Natural products 0.000 description 2
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 108020005544 Antisense RNA Proteins 0.000 description 2
- 101150111062 C gene Proteins 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 102000012410 DNA Ligases Human genes 0.000 description 2
- 108010061982 DNA Ligases Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 208000009386 Experimental Arthritis Diseases 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 2
- 108010002386 Interleukin-3 Proteins 0.000 description 2
- 102000000646 Interleukin-3 Human genes 0.000 description 2
- 101150008942 J gene Proteins 0.000 description 2
- 102000008072 Lymphokines Human genes 0.000 description 2
- 108010074338 Lymphokines Proteins 0.000 description 2
- 241001049988 Mycobacterium tuberculosis H37Ra Species 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 108091007960 PI3Ks Proteins 0.000 description 2
- KHGNFPUMBJSZSM-UHFFFAOYSA-N Perforine Natural products COC1=C2CCC(O)C(CCC(C)(C)O)(OC)C2=NC2=C1C=CO2 KHGNFPUMBJSZSM-UHFFFAOYSA-N 0.000 description 2
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 description 2
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 2
- SBVPYBFMIGDIDX-SRVKXCTJSA-N Pro-Pro-Pro Chemical compound OC(=O)[C@@H]1CCCN1C(=O)[C@H]1N(C(=O)[C@H]2NCCC2)CCC1 SBVPYBFMIGDIDX-SRVKXCTJSA-N 0.000 description 2
- 101100179076 Rattus norvegicus Icos gene Proteins 0.000 description 2
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 2
- 238000002105 Southern blotting Methods 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 208000038016 acute inflammation Diseases 0.000 description 2
- 230000006022 acute inflammation Effects 0.000 description 2
- 229960000643 adenine Drugs 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 208000037976 chronic inflammation Diseases 0.000 description 2
- 230000006020 chronic inflammation Effects 0.000 description 2
- 101150076615 ck gene Proteins 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 239000003184 complementary RNA Substances 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 229940104302 cytosine Drugs 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 210000004443 dendritic cell Anatomy 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 239000000710 homodimer Substances 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 230000005732 intercellular adhesion Effects 0.000 description 2
- 230000031261 interleukin-10 production Effects 0.000 description 2
- 230000004073 interleukin-2 production Effects 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 238000002350 laparotomy Methods 0.000 description 2
- 239000004816 latex Substances 0.000 description 2
- 229920000126 latex Polymers 0.000 description 2
- 229920006008 lipopolysaccharide Polymers 0.000 description 2
- 229940057995 liquid paraffin Drugs 0.000 description 2
- 210000005228 liver tissue Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- 230000035407 negative regulation of cell proliferation Effects 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 210000004798 organs belonging to the digestive system Anatomy 0.000 description 2
- 210000002741 palatine tonsil Anatomy 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000000149 penetrating effect Effects 0.000 description 2
- 229930192851 perforin Natural products 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 210000001539 phagocyte Anatomy 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 230000001235 sensitizing effect Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 208000008732 thymoma Diseases 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 238000011830 transgenic mouse model Methods 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 229940035893 uracil Drugs 0.000 description 2
- STGXGJRRAJKJRG-JDJSBBGDSA-N (3r,4r,5r)-5-(hydroxymethyl)-3-methoxyoxolane-2,4-diol Chemical compound CO[C@H]1C(O)O[C@H](CO)[C@H]1O STGXGJRRAJKJRG-JDJSBBGDSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
- UJBCLAXPPIDQEE-UHFFFAOYSA-N 5-prop-1-ynyl-1h-pyrimidine-2,4-dione Chemical compound CC#CC1=CNC(=O)NC1=O UJBCLAXPPIDQEE-UHFFFAOYSA-N 0.000 description 1
- MSSXOMSJDRHRMC-UHFFFAOYSA-N 9H-purine-2,6-diamine Chemical compound NC1=NC(N)=C2NC=NC2=N1 MSSXOMSJDRHRMC-UHFFFAOYSA-N 0.000 description 1
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 1
- 108010082126 Alanine transaminase Proteins 0.000 description 1
- 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 1
- 102000005738 B7 Antigens Human genes 0.000 description 1
- 108010045634 B7 Antigens Proteins 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 108010029697 CD40 Ligand Proteins 0.000 description 1
- 102100032937 CD40 ligand Human genes 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 1
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 1
- 206010057248 Cell death Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241001524679 Escherichia virus M13 Species 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 102100029203 F-box only protein 8 Human genes 0.000 description 1
- 208000034454 F12-related hereditary angioedema with normal C1Inh Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 101710154606 Hemagglutinin Proteins 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 101000777314 Homo sapiens Choline kinase alpha Proteins 0.000 description 1
- 101000777313 Homo sapiens Choline/ethanolamine kinase Proteins 0.000 description 1
- 101100334493 Homo sapiens FBXO8 gene Proteins 0.000 description 1
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 description 1
- 101000918926 Homo sapiens Sphingolipid delta(4)-desaturase/C4-monooxygenase DES2 Proteins 0.000 description 1
- 101001138544 Homo sapiens UMP-CMP kinase Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 102000016844 Immunoglobulin-like domains Human genes 0.000 description 1
- 108050006430 Immunoglobulin-like domains Proteins 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 102000000743 Interleukin-5 Human genes 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 101150075078 MEP10 gene Proteins 0.000 description 1
- 102000043129 MHC class I family Human genes 0.000 description 1
- 108091054437 MHC class I family Proteins 0.000 description 1
- 101000777315 Mus musculus Choline kinase alpha Proteins 0.000 description 1
- 101000777310 Mus musculus Choline/ethanolamine kinase Proteins 0.000 description 1
- 101100020679 Mus musculus Lcn5 gene Proteins 0.000 description 1
- 101000974705 Mus musculus UMP-CMP kinase Proteins 0.000 description 1
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 1
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 1
- 102000038030 PI3Ks Human genes 0.000 description 1
- 241000609499 Palicourea Species 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 108010047620 Phytohemagglutinins Proteins 0.000 description 1
- 206010035148 Plague Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 101710176177 Protein A56 Proteins 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 102100037205 Sal-like protein 2 Human genes 0.000 description 1
- 101710192308 Sal-like protein 2 Proteins 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 102000005686 Serum Globulins Human genes 0.000 description 1
- 108010045362 Serum Globulins Proteins 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 102100029473 Sphingolipid delta(4)-desaturase/C4-monooxygenase DES2 Human genes 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- -1 TNFQ Proteins 0.000 description 1
- 206010054094 Tumour necrosis Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 229960003896 aminopterin Drugs 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical class N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 238000012870 ammonium sulfate precipitation Methods 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000781 anti-lymphocytic effect Effects 0.000 description 1
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 230000003305 autocrine Effects 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000035584 blastogenesis Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000012219 cassette mutagenesis Methods 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 239000002458 cell surface marker Substances 0.000 description 1
- 230000005889 cellular cytotoxicity Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 101150034144 ci gene Proteins 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 230000001461 cytolytic effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 201000002491 encephalomyelitis Diseases 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 210000000224 granular leucocyte Anatomy 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 239000000185 hemagglutinin Substances 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 208000016861 hereditary angioedema type 3 Diseases 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 210000003917 human chromosome Anatomy 0.000 description 1
- 210000005104 human peripheral blood lymphocyte Anatomy 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 229940076144 interleukin-10 Drugs 0.000 description 1
- 108040006849 interleukin-2 receptor activity proteins Proteins 0.000 description 1
- 230000003996 interleukin-20 production Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000031146 intracellular signal transduction Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000005067 joint tissue Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 238000007885 magnetic separation Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 210000000713 mesentery Anatomy 0.000 description 1
- YACKEPLHDIMKIO-UHFFFAOYSA-L methylphosphonate(2-) Chemical compound CP([O-])([O-])=O YACKEPLHDIMKIO-UHFFFAOYSA-L 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 230000033607 mismatch repair Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 210000002850 nasal mucosa Anatomy 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000014207 opsonization Effects 0.000 description 1
- 238000007500 overflow downdraw method Methods 0.000 description 1
- 101710135378 pH 6 antigen Proteins 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 210000004976 peripheral blood cell Anatomy 0.000 description 1
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000001885 phytohemagglutinin Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 235000019419 proteases Nutrition 0.000 description 1
- 210000001938 protoplast Anatomy 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 230000019908 regulation of T cell activation Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 150000003291 riboses Chemical class 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- YEENEYXBHNNNGV-XEHWZWQGSA-M sodium;3-acetamido-5-[acetyl(methyl)amino]-2,4,6-triiodobenzoate;(2r,3r,4s,5s,6r)-2-[(2r,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound [Na+].CC(=O)N(C)C1=C(I)C(NC(C)=O)=C(I)C(C([O-])=O)=C1I.O[C@H]1[C@H](O)[C@@H](CO)O[C@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 YEENEYXBHNNNGV-XEHWZWQGSA-M 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 108010075242 streptolysin S Proteins 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 229940075420 xanthine Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Rheumatology (AREA)
- Marine Sciences & Fisheries (AREA)
- Zoology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP24267299 | 1999-08-30 | ||
| JP2000254680 | 2000-08-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200103314B true ZA200103314B (en) | 2001-11-22 |
Family
ID=26535864
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200103314A ZA200103314B (en) | 1999-08-30 | 2001-04-24 | A pharmaceutical composition for treating immune diseases. |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US7465445B2 (fr) |
| EP (1) | EP1125585B1 (fr) |
| JP (1) | JP3871503B2 (fr) |
| KR (2) | KR100609441B1 (fr) |
| CN (2) | CN101028519B (fr) |
| AT (1) | ATE517925T1 (fr) |
| AU (1) | AU6865000A (fr) |
| BR (1) | BR0007047A (fr) |
| CA (1) | CA2348954C (fr) |
| CZ (1) | CZ304013B6 (fr) |
| HK (1) | HK1040489A1 (fr) |
| HU (1) | HU228575B1 (fr) |
| ID (1) | ID30042A (fr) |
| IL (2) | IL142691A0 (fr) |
| NO (2) | NO332264B1 (fr) |
| NZ (1) | NZ529577A (fr) |
| RU (1) | RU2203682C2 (fr) |
| SK (1) | SK288074B6 (fr) |
| TR (1) | TR200101205T1 (fr) |
| WO (1) | WO2001015732A1 (fr) |
| ZA (1) | ZA200103314B (fr) |
Families Citing this family (79)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7112655B1 (en) | 1997-02-27 | 2006-09-26 | Japan Tobacco, Inc. | JTT-1 protein and methods of inhibiting lymphocyte activation |
| JP3521382B2 (ja) | 1997-02-27 | 2004-04-19 | 日本たばこ産業株式会社 | 細胞間接着及びシグナル伝達を媒介する細胞表面分子 |
| US7435796B1 (en) | 1999-02-03 | 2008-10-14 | Amgen Inc. | Antibodies which bind B7RP1 |
| DK2332978T3 (da) | 1999-02-03 | 2014-06-23 | Amgen Inc | Nye polypeptider, der er involveret ved et immunrespons |
| US7708993B2 (en) | 1999-02-03 | 2010-05-04 | Amgen Inc. | Polypeptides involved in immune response |
| US8624010B1 (en) | 1999-02-03 | 2014-01-07 | Steven K. Yoshinaga | Nucleic acids encoding B7RP1 |
| JP3871503B2 (ja) | 1999-08-30 | 2007-01-24 | 日本たばこ産業株式会社 | 免疫性疾患治療剤 |
| JP4210454B2 (ja) * | 2001-03-27 | 2009-01-21 | 日本たばこ産業株式会社 | 炎症性腸疾患治療剤 |
| US7879840B2 (en) | 2005-08-25 | 2011-02-01 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the RyR receptors |
| US8022058B2 (en) | 2000-05-10 | 2011-09-20 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the RyR receptors |
| US7718644B2 (en) | 2004-01-22 | 2010-05-18 | The Trustees Of Columbia University In The City Of New York | Anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof |
| JP3597140B2 (ja) * | 2000-05-18 | 2004-12-02 | 日本たばこ産業株式会社 | 副刺激伝達分子ａｉｌｉｍに対するヒトモノクローナル抗体及びその医薬用途 |
| US7220822B2 (en) * | 2000-11-22 | 2007-05-22 | The Ohio State University | CD28 mimetics for blocking T cell mediated immune reactions |
| JP4212278B2 (ja) | 2001-03-01 | 2009-01-21 | 日本たばこ産業株式会社 | 移植片拒絶反応抑制剤 |
| US8710045B2 (en) | 2004-01-22 | 2014-04-29 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the ryanodine receptors |
| US7704990B2 (en) | 2005-08-25 | 2010-04-27 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the RyR receptors |
| US20080279851A1 (en) * | 2007-05-07 | 2008-11-13 | Medlmmune, Llc | Anti-icos antibodies and their use in treatment of oncology, transplantation and autoimmune disease |
| EP2691419B1 (fr) * | 2011-03-31 | 2016-11-09 | INSERM - Institut National de la Santé et de la Recherche Médicale | Anticorps dirigés contre icos et utilisation de ceux-ci |
| DE102011006809A1 (de) | 2011-04-05 | 2012-10-11 | Freistaat Bayern vertreten durch die Julius-Maximilians-Universität Würzburg | Verwendung eines Mittels aus Antikörpern und/oder Insulin-like growth factor-Antagonisten |
| EP2717887B1 (fr) | 2011-06-09 | 2017-12-27 | University of Florida Research Foundation, Inc. | Méthodes de traitement ou de prévention d'une maladie du greffon contre l'hôte |
| EP2892928B1 (fr) * | 2012-09-03 | 2018-05-30 | INSERM - Institut National de la Santé et de la Recherche Médicale | Anticorps anti-icos pour traiter la maladie du greffon contre l'hôte |
| JOP20140087B1 (ar) | 2013-03-13 | 2021-08-17 | Amgen Inc | بروتينات مخصصة ل baff و b7rp1 وإستخداماتها |
| US9458246B2 (en) | 2013-03-13 | 2016-10-04 | Amgen Inc. | Proteins specific for BAFF and B7RP1 |
| GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
| MA41414A (fr) | 2015-01-28 | 2017-12-05 | Centre Nat Rech Scient | Protéines de liaison agonistes d' icos |
| MX363780B (es) | 2015-12-03 | 2019-04-03 | Glaxosmithkline Ip Dev Ltd | Dinucleótidos de purina cíclica como moduladores del estimulador de los genes de interferón. |
| WO2017098421A1 (fr) | 2015-12-08 | 2017-06-15 | Glaxosmithkline Intellectual Property Development Limited | Composés benzothiadiazine |
| WO2017153952A1 (fr) | 2016-03-10 | 2017-09-14 | Glaxosmithkline Intellectual Property Development Limited | Dérivés de 5-sulfamoyl-2-hydroxybenzamide |
| AU2017247806B2 (en) | 2016-04-07 | 2019-11-14 | Glaxosmithkline Intellectual Property Development Limited | Heterocyclic amides useful as protein modulators |
| NZ745957A (en) | 2016-04-07 | 2020-07-31 | Glaxosmithkline Ip Dev Ltd | Heterocyclic amides useful as protein modulators |
| CN109328188A (zh) | 2016-05-05 | 2019-02-12 | 葛兰素史密斯克莱知识产权（第2 号）有限公司 | Zeste增强子同源物2抑制剂 |
| WO2018029474A2 (fr) | 2016-08-09 | 2018-02-15 | Kymab Limited | Anticorps anti-icos |
| WO2017220990A1 (fr) | 2016-06-20 | 2017-12-28 | Kymab Limited | Anticorps anti-pd-l1 |
| US9567399B1 (en) | 2016-06-20 | 2017-02-14 | Kymab Limited | Antibodies and immunocytokines |
| KR20190028540A (ko) | 2016-07-20 | 2019-03-18 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | Perk 억제제로서의 이소퀴놀린 유도체 |
| EP3497128A2 (fr) | 2016-08-09 | 2019-06-19 | Kymab Limited | Anticorps anti-icos |
| EP3534947A1 (fr) | 2016-11-03 | 2019-09-11 | Kymab Limited | Anticorps, combinaisons comprenant des anticorps, biomarqueurs, utilisations et procédés |
| BR112019012901A2 (pt) | 2016-12-22 | 2020-01-07 | Daiichi Sankyo Company, Limited | Anticorpo ou fragmento de ligação a antígeno do anticorpo, polinucleotídeo, vetor, célula, métodos para produzir um anticorpo ou um fragmento de ligação a antígeno do anticorpo e uma molécula que se ligue ao cd3 humano e ao cd3 de macaco cinomolgo, composição farmacêutica, e, molécula |
| JP2020509009A (ja) | 2017-02-27 | 2020-03-26 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | キナーゼ阻害剤としての複素環式アミド |
| TWI788340B (zh) | 2017-04-07 | 2023-01-01 | 美商必治妥美雅史谷比公司 | 抗icos促效劑抗體及其用途 |
| BR112019025257A2 (pt) | 2017-06-09 | 2020-09-29 | Glaxosmithkline Intellectual Property Development Limited | método para tratar câncer, e, anticorpo anti-icos ou porção de ligação ao antígeno do mesmo e um anticorpo anti-ox40 ou porção de ligação ao antígeno do mesmo |
| CA3066048A1 (fr) | 2017-06-09 | 2018-12-13 | Glaxosmithkline Intellectual Property Development Limited | Polytherapie |
| JP2020522541A (ja) | 2017-06-09 | 2020-07-30 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | 癌を治療するためのｉｃｏｓアゴニストおよびｏｘ４０アゴニストでの組み合わせ療法 |
| GB201709808D0 (en) | 2017-06-20 | 2017-08-02 | Kymab Ltd | Antibodies |
| WO2019021208A1 (fr) | 2017-07-27 | 2019-01-31 | Glaxosmithkline Intellectual Property Development Limited | Dérivés d'indazole utiles en tant qu'inhibiteurs de perk |
| WO2019053617A1 (fr) | 2017-09-12 | 2019-03-21 | Glaxosmithkline Intellectual Property Development Limited | Composés chimiques |
| CN111094353A (zh) | 2017-09-14 | 2020-05-01 | 葛兰素史密斯克莱知识产权发展有限公司 | 用于癌症的组合治疗 |
| CA3077337A1 (fr) | 2017-10-05 | 2019-04-11 | Glaxosmithkline Intellectual Property Development Limited | Modulateurs de stimulateur des genes (sting) de l'interferon |
| WO2019069269A1 (fr) | 2017-10-05 | 2019-04-11 | Glaxosmithkline Intellectual Property Development Limited | Modulateurs de stimulateur des gènes (sting) d'interféron utiles dans le traitement du vih |
| GB201721338D0 (en) | 2017-12-19 | 2018-01-31 | Kymab Ltd | Anti-icos Antibodies |
| US11629189B2 (en) | 2017-12-19 | 2023-04-18 | Kymab Limited | Bispecific antibody for ICOS and PD-L1 |
| GB201807924D0 (en) | 2018-05-16 | 2018-06-27 | Ctxt Pty Ltd | Compounds |
| BR112020023451A2 (pt) | 2018-05-31 | 2021-02-23 | Glaxosmithkline Intellectual Property Development Limited | terapia combinada |
| BR112020023459A2 (pt) | 2018-05-31 | 2021-02-23 | Glaxosmithkline Intellectual Property Development Limited | terapia combinada com proteínas de ligação a icos e inibidores de arginina metiltransferase |
| WO2019241730A2 (fr) | 2018-06-15 | 2019-12-19 | Flagship Pioneering Innovations V, Inc. | Augmentation de l'activité immunitaire par modulation de facteurs de signalisation post-cellulaires |
| WO2020031087A1 (fr) | 2018-08-06 | 2020-02-13 | Glaxosmithkline Intellectual Property Development Limited | Polythérapie |
| US20210324081A1 (en) | 2018-10-22 | 2021-10-21 | Glaxosmithkline Intellectual Property Development Limited | Dosing |
| MA55805A (fr) | 2019-05-03 | 2022-03-09 | Flagship Pioneering Innovations V Inc | Métodes de modulation de l'activité immunitaire |
| GB201910305D0 (en) | 2019-07-18 | 2019-09-04 | Ctxt Pty Ltd | Compounds |
| GB201910304D0 (en) | 2019-07-18 | 2019-09-04 | Ctxt Pty Ltd | Compounds |
| WO2021018941A1 (fr) | 2019-07-31 | 2021-02-04 | Glaxosmithkline Intellectual Property Development Limited | Méthodes de traitement du cancer |
| WO2021043961A1 (fr) | 2019-09-06 | 2021-03-11 | Glaxosmithkline Intellectual Property Development Limited | Schéma posologique pour le traitement du cancer avec un anticorps agoniste anti-icos et une chimiothérapie |
| WO2021046293A1 (fr) | 2019-09-06 | 2021-03-11 | Glaxosmithkline Intellectual Property Development Limited | Schéma posologique pour le traitement du cancer avec un anticorps agoniste anti-icos et du trémélimumab |
| AU2020355614A1 (en) | 2019-09-27 | 2022-04-14 | Glaxosmithkline Intellectual Property Development Limited | Antigen binding proteins |
| EP4076434A1 (fr) | 2019-12-17 | 2022-10-26 | Flagship Pioneering Innovations V, Inc. | Polythérapies anticancéreuses ayant des inducteurs de désassemblage cellulaire dépendant du fer |
| CA3171597A1 (fr) | 2020-04-14 | 2021-10-21 | Glaxosmithkline Intellectual Property Development Limited | Traitement combine pour le cancer |
| WO2021209357A1 (fr) | 2020-04-14 | 2021-10-21 | Glaxosmithkline Intellectual Property Development Limited | Traitement combiné pour le cancer impliquant des anticorps anti-icos et anti-pd1, impliquant éventuellement en outre des anticorps anti-tim3 |
| AU2021256925A1 (en) | 2020-04-14 | 2022-11-03 | Ares Trading S.A. | Combination treatment for cancer based upon an ICOS antibody and a PD-L1 antibody TGF-beta-receptor fusion protein |
| GB202007099D0 (en) | 2020-05-14 | 2020-07-01 | Kymab Ltd | Tumour biomarkers for immunotherapy |
| US20230355804A1 (en) | 2020-06-29 | 2023-11-09 | Flagship Pioneering Innovations V, Inc. | Viruses engineered to promote thanotransmission and their use in treating cancer |
| MX2023010067A (es) | 2021-03-02 | 2023-09-06 | Glaxosmithkline Ip Dev Ltd | Piridinas sustituidas como inhibidores de dnmt1. |
| WO2022208353A1 (fr) | 2021-03-31 | 2022-10-06 | Glaxosmithkline Intellectual Property Development Limited | Protéines de liaison à l'antigène et leurs combinaisons |
| WO2022212784A1 (fr) | 2021-03-31 | 2022-10-06 | Flagship Pioneering Innovations V, Inc. | Polypeptides de thanotransmission et leur utilisation dans le traitement du cancer |
| CA3219336A1 (fr) | 2021-05-18 | 2022-11-24 | Kymab Limited | Utilisations d'anticorps anti-icos |
| GB202107994D0 (en) | 2021-06-04 | 2021-07-21 | Kymab Ltd | Treatment of cancer |
| CA3224374A1 (fr) | 2021-06-29 | 2023-01-05 | Flagship Pioneering Innovations V, Inc. | Cellules immunitaires modifiees pour favoriser la thanotransmission de phenylethanolamines et leurs utilisations |
| WO2023222854A1 (fr) | 2022-05-18 | 2023-11-23 | Kymab Limited | Utilisations d'anticorps anti-icos |
| WO2024077191A1 (fr) | 2022-10-05 | 2024-04-11 | Flagship Pioneering Innovations V, Inc. | Molécules d'acide nucléique codant pour des trif et des polypeptides supplémentaires et leur utilisation dans le traitement du cancer |
| WO2024151687A1 (fr) | 2023-01-09 | 2024-07-18 | Flagship Pioneering Innovations V, Inc. | Commutateurs génétiques et leur utilisation dans le traitement du cancer |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5506126A (en) | 1988-02-25 | 1996-04-09 | The General Hospital Corporation | Rapid immunoselection cloning method |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6641809B1 (en) | 1990-03-26 | 2003-11-04 | Bristol-Myers Squibb Company | Method of regulating cellular processes mediated by B7 and CD28 |
| US5770197A (en) | 1991-06-27 | 1998-06-23 | Bristol-Myers Squibb Company | Methods for regulating the immune response using B7 binding molecules and IL4-binding molecules |
| JP3162438B2 (ja) | 1991-09-12 | 2001-04-25 | 住友製薬株式会社 | 高感度特異的抗体測定法 |
| US5484892A (en) | 1993-05-21 | 1996-01-16 | Dana-Farber Cancer Institute, Inc. | Monoclonal antibodies that block ligand binding to the CD22 receptor in mature B cells |
| US6719972B1 (en) | 1994-06-03 | 2004-04-13 | Repligen Corporation | Methods of inhibiting T cell proliferation or IL-2 accumulation with CTLA4- specific antibodies |
| US5747461A (en) | 1994-07-26 | 1998-05-05 | Markov; Angel K. | Synergistic administration of cyclosporine and fructose diphosphate |
| US6440418B1 (en) * | 1995-11-07 | 2002-08-27 | Idec Pharmaceuticals Corporation | Methods of treating autoimmune diseases with gp39-specific antibodies |
| US5914112A (en) | 1996-01-23 | 1999-06-22 | Genentech, Inc. | Anti-CD18 antibodies in stroke |
| DK0877626T3 (da) | 1996-01-23 | 2002-12-30 | Univ Vermont | Anti-CD18 antistoffer til anvendelse mod slagtilfælde |
| CA2266346A1 (fr) | 1996-09-18 | 1998-03-26 | Zetesis S.P.A. | Utilisation de proteines comme agents actifs contre des maladies auto-immunes |
| DE69739725D1 (de) | 1996-11-08 | 2010-02-11 | Biogen Idec Inc | Identifikation von bindungs- interaktionen zwischen gewissen antikorpern und den humanen costimulatorischen antigenen b7.1 (cd80) und b7.2 (cd28) |
| CA2194814A1 (fr) * | 1997-01-10 | 1998-07-10 | Terry L. Delovitch | Stimulation des cellules t protectrices pour prevenir les maladies auto-immunes |
| AU4145597A (en) | 1997-02-20 | 1998-09-09 | Cedars-Sinai Medical Center | Ulcerative colitis panca secretory vesicle antigen and methods of using sa me |
| US7112655B1 (en) | 1997-02-27 | 2006-09-26 | Japan Tobacco, Inc. | JTT-1 protein and methods of inhibiting lymphocyte activation |
| JP3521382B2 (ja) | 1997-02-27 | 2004-04-19 | 日本たばこ産業株式会社 | 細胞間接着及びシグナル伝達を媒介する細胞表面分子 |
| NZ500078A (en) | 1997-04-07 | 2001-10-26 | Genentech Inc | Humanized anti-VEGF antibodies and their use in inhibiting VEGF-induced angiogenesis in mammals |
| CN1202864C (zh) * | 1997-05-17 | 2005-05-25 | 拜奥根有限公司 | Cd40:cd154结合阻断物在制备预防逆适应性免疫应答,特别是移植物排斥反应的药物中的用途 |
| DE19821060A1 (de) | 1997-09-23 | 1999-04-15 | Bundesrepublik Deutschland Let | Ko-stimulierendes Polypeptid von T-Zellen, monoklonale Antikörper sowie die Herstellung und deren Verwendung |
| US7259247B1 (en) | 1997-09-23 | 2007-08-21 | Bundersrespublik Deutschaland Letztvertreten Durch Den Direktor Des Robert-Koch-Institutes | Anti-human T-cell costimulating polypeptide monoclonal antibodies |
| JPH11228442A (ja) | 1998-02-09 | 1999-08-24 | Cypros Pharmaceut Corp | 臓器移植後のシクロスポリン投与量を低減するためのフルクトース二リン酸の使用 |
| JP2000154151A (ja) | 1998-09-14 | 2000-06-06 | Kyo Jo | 免疫抑制剤 |
| AU767241B2 (en) | 1998-09-14 | 2003-11-06 | Qiang Xu | Immunosuppressive agents |
| JP2003532370A (ja) | 1998-10-07 | 2003-11-05 | ミレニアム・ファーマシューティカルズ・インコーポレイテッド | 新規なＴｈ２特異的分子およびその使用方法 |
| DK2332978T3 (da) | 1999-02-03 | 2014-06-23 | Amgen Inc | Nye polypeptider, der er involveret ved et immunrespons |
| WO2000067788A2 (fr) | 1999-05-06 | 2000-11-16 | Genetics Institute, Inc. | Emploi de molecules de co-stimulation solubles favorisant les reponses immunitaires |
| US6613327B1 (en) | 1999-07-28 | 2003-09-02 | Genetics Institute, Inc. | Methods of preventing immune-mediated abortion by inhibiting a CD28-mediated costimulatory signal |
| AU6458400A (en) | 1999-08-11 | 2001-03-13 | Isis Innovation Limited | Nucleic acid, polypeptides, assays, therapeutic methods and means |
| JP4210454B2 (ja) | 2001-03-27 | 2009-01-21 | 日本たばこ産業株式会社 | 炎症性腸疾患治療剤 |
| JP3871503B2 (ja) | 1999-08-30 | 2007-01-24 | 日本たばこ産業株式会社 | 免疫性疾患治療剤 |
| JP2003508088A (ja) | 1999-09-03 | 2003-03-04 | ヒューマン ジノーム サイエンシーズ， インコーポレイテッド | ５２個のヒト分泌タンパク質 |
| EP1218504B1 (fr) | 1999-09-21 | 2007-07-11 | Genetics Institute, LLC | Molecules gl50 et leurs utilisations |
| CA2386641A1 (fr) | 1999-10-29 | 2001-05-10 | Human Genome Sciences, Inc. | 32 proteines humaines secretees |
| WO2001064704A1 (fr) | 2000-03-02 | 2001-09-07 | Mayo Foundation For Medical Education And Research | LA hB7-H2, NOUVELLE MOLECULE CO-STIMULANTE |
| JP3597140B2 (ja) | 2000-05-18 | 2004-12-02 | 日本たばこ産業株式会社 | 副刺激伝達分子ａｉｌｉｍに対するヒトモノクローナル抗体及びその医薬用途 |
| WO2002044364A2 (fr) | 2000-11-28 | 2002-06-06 | Amgen Inc. | Nouveaux polypeptides impliques dans la reponse immunitaire |
| JP4212278B2 (ja) | 2001-03-01 | 2009-01-21 | 日本たばこ産業株式会社 | 移植片拒絶反応抑制剤 |
-
2000
- 2000-08-29 JP JP2000258470A patent/JP3871503B2/ja not_active Expired - Fee Related
- 2000-08-30 TR TR2001/01205T patent/TR200101205T1/xx unknown
- 2000-08-30 IL IL14269100A patent/IL142691A0/xx unknown
- 2000-08-30 HU HU0200994A patent/HU228575B1/hu not_active IP Right Cessation
- 2000-08-30 RU RU2001114516/14A patent/RU2203682C2/ru not_active IP Right Cessation
- 2000-08-30 BR BR0007047-5A patent/BR0007047A/pt active Search and Examination
- 2000-08-30 SK SK732-2001A patent/SK288074B6/sk not_active IP Right Cessation
- 2000-08-30 CN CN2006101006481A patent/CN101028519B/zh not_active Expired - Fee Related
- 2000-08-30 CN CN00802420A patent/CN1359302A/zh active Pending
- 2000-08-30 KR KR1020017005279A patent/KR100609441B1/ko not_active IP Right Cessation
- 2000-08-30 AT AT00956800T patent/ATE517925T1/de not_active IP Right Cessation
- 2000-08-30 CZ CZ20011720A patent/CZ304013B6/cs not_active IP Right Cessation
- 2000-08-30 KR KR10-2004-7001435A patent/KR20040028960A/ko not_active Application Discontinuation
- 2000-08-30 NZ NZ529577A patent/NZ529577A/en not_active IP Right Cessation
- 2000-08-30 WO PCT/JP2000/005868 patent/WO2001015732A1/fr active IP Right Grant
- 2000-08-30 CA CA2348954A patent/CA2348954C/fr not_active Expired - Fee Related
- 2000-08-30 EP EP00956800A patent/EP1125585B1/fr not_active Expired - Lifetime
- 2000-08-30 ID IDW00200101165A patent/ID30042A/id unknown
- 2000-08-30 AU AU68650/00A patent/AU6865000A/en not_active Abandoned
-
2001
- 2001-04-19 IL IL142691A patent/IL142691A/en not_active IP Right Cessation
- 2001-04-24 ZA ZA200103314A patent/ZA200103314B/en unknown
- 2001-04-27 NO NO20012105A patent/NO332264B1/no not_active IP Right Cessation
-
2002
- 2002-02-22 HK HK02101307.4A patent/HK1040489A1/zh unknown
-
2003
- 2003-12-05 US US10/729,880 patent/US7465445B2/en not_active Expired - Fee Related
-
2008
- 2008-08-26 NO NO20083674A patent/NO20083674L/no not_active Application Discontinuation
- 2008-11-11 US US12/268,832 patent/US7998478B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7998478B2 (en) | Pharmaceutical composition for treating immune diseases | |
| RU2281118C2 (ru) | Средства для лечения воспалительных кишечных заболеваний | |
| ES2347758T3 (es) | Anticuerpo monoclonal humano contra la molecula ailim coestimuladora y transductora de señales y uso farmaceutico del mismo. | |
| KR100609444B1 (ko) | 이식편 거절반응 억제제 | |
| CN106061999A (zh) | Il‑21抗体 | |
| US20230015969A1 (en) | Regulatory t cell mediator proteins and uses thereof | |
| KR20230015348A (ko) | Th2 개재성 질환을 치료 또는 예방하기 위한 PD-1 작용제 함유 의약 조성물 | |
| AU2003262479B2 (en) | A Pharmaceutical Composition for Treating Immune Diseases | |
| MXPA01004315A (en) | Remedies for immunological diseases | |
| JP3543966B2 (ja) | 副刺激伝達分子ａｉｌｉｍに対するヒトモノクローナル抗体及びその医薬用途 | |
| JP2004261182A (ja) | 副刺激伝達分子ａｉｌｉｍに対するヒトモノクローナル抗体及びその医薬用途 | |
| ZA200306516B (en) | Graft rejection inhibitors. |